Do we have available eligible data on the cost of medicines in the Slovak Republic?
Existence of information asymmetry in the area of drug consumption. Why is it created and we know / want to remove it? Based on which data is it possible to make clear decisions? For correct interpretation of data, it is necessary to know the sources of data and their detailed structure. In order to compare consumption data, it is therefore necessary to compare the same data structure, otherwise incorrect assumptions arise leading to the same quality of decisions.
Sign in to Autumn ITAPA 2024
Iveta Palešová
Iveta Palešová is a graduate of the University of Economics in Bratislava, Faculty of Business Management. Since 1995 she has been working in the pharmaceutical industry. She started her professional career at Janssen-Cilag, where she worked for several positions in finance, logistics and pricing in a regulated environment. Since 2008, she has been involved in drug pricing, market entry, pharmaco-economic budget and cost analyzes in various therapeutic areas, data processing on drug consumption development, complex medical costs, and treatment effects. She worked at Roche 2008-2014, Amgen 2014-2017, and Novaris from 2017 until now. She has recently been particularly involved in the advent of oncology drugs. She is an active member of the…
See more info about the speaker
